使用利妥昔单抗且既往bDMARD失败次数较少的类风湿性关节炎患者可能比使用全剂量的患者有效减少利妥昔mab剂量，并经历更少的严重不良事件：一项5年队列研究

IF 4.4 2区医学 Q1 RHEUMATOLOGY

Arthritis Research & Therapy Pub Date : 2022-06-02 DOI:10.1186/s13075-022-02826-6

A. Bertsias, N. Avgoustidis, I. Papalopoulos, A. Repa, N. Kougkas, E. Kalogiannaki, Georgios Bertsias, I. Flouri, P. Sidiropoulos

引用次数: 1

摘要

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Rheumatoid arthritis patients initiating rituximab with low number of previous bDMARDs failures may effectively reduce rituximab dose and experience fewer serious adverse events than patients on full dose: a 5-year cohort study

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Arthritis Research & Therapy RHEUMATOLOGY-

CiteScore

8.30

自引率

2.00%

发文量

261

审稿时长

2.3 months

期刊介绍： Established in 1999, Arthritis Research and Therapy is an international, open access, peer-reviewed journal, publishing original articles in the area of musculoskeletal research and therapy as well as, reviews, commentaries and reports. A major focus of the journal is on the immunologic processes leading to inflammation, damage and repair as they relate to autoimmune rheumatic and musculoskeletal conditions, and which inform the translation of this knowledge into advances in clinical care. Original basic, translational and clinical research is considered for publication along with results of early and late phase therapeutic trials, especially as they pertain to the underpinning science that informs clinical observations in interventional studies.